Article Text

other Versions

Ranibizumab for exudative age-related macular degeneration: 24 months outcomes from a single-center institutional setting
  1. Giuseppe Querques1,*,
  2. Sophie Azrya1,
  3. Domenico Martinelli2,
  4. Elya Berboucha1,
  5. Audrey Feldman1,
  6. Alfredo Pece3,
  7. Gabriel Coscas1,
  8. Gisele Soubrane1,
  9. Eric Souied1
  1. 1 Uninersity Paris XII, France;
  2. 2 University of Bari, Italy;
  3. 3 Retina 3000 Foundation, Italy
  1. Correspondence to: Giuseppe Querques, Ophthalmology, University of Foggia, University Paris XII, viale degli aviatori, 108/a, Foggia, 71100, Italy; giuseppe.querques{at}


Background: To analyze the 24-month outcomes of intravitreal ranibizumab injections for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods: We reviewed the charts of all consecutive eyes with CNV secondary to AMD, who underwent 1 intravitreal ranibizumab injection (followed by a pro re nata [1+PRN] decision to retreat or to not retreat) at least 24 months before. Best-corrected visual acuity (BCVA) changes and central macular thickness (CMT) were retrospectively assessed, from baseline (m 0) to month 12 (m12), and 24 (m24).

Results: Ninety-six eyes of 79 patients (23 male, 56 female, aged 63 - 90 years) were included for analysis. The number of intravitreal injections administered ranged from 1 to 16. Mean BCVA significantly improved from m0 (0.78±0.33) to m12 (0.61±0.39, p<0.001), and m24 (0.65±0.38, p<0.001). Mean CMT significantly decreased from m0 (323.7±118.1) to m12 (254.6±92.3, p<0.001), and m24 (259.0±89.9, p<0.001). At m24, sub-retinal fluid, cystoid macular edema and pigment epithelium detachment were present in fewer eyes (13, 31 and 31 eyes respectively), compared with m0 (33, 61 and 72 eyes, respectively).

Overall, at m12 and m24, 91 eyes (94.8%) and 84 eyes (87.5%) lost fewer than 15 letters, and 25 (26%) eyes and 24 eyes (25%) improved by 15 letters or more, respectively; 5 eyes (5.2%) and 12 eyes (12.5%) lost more than15 letters, at m12 and m24, respectively.

Conclusion: In our study, similarly to other studies of variable dosing regimen over 24 months, intravitreal ranibizumab was effective in significantly increasing BCVA and reducing CMT.

Statistics from


    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.